Exploring the Anti-Cancer Potential of Siddha Formulation <i>Vaalai Rasa Mezhugu</i> (VRM) on TM3 Testicular Cancer Cells: An In Vitro Study
2025
Suresh Ramasamy | Siva Annamalai | Kiruba Annammal PAA Antony Raj | Senthamil Selvi Gopalan | Abarna Balasubramani
Testicular cancer (TC) is common in men aged 14 to 44 and has been increasing for the past two decades. The Siddha practice of medicine contains many herbo-mineral formulations for cancer treatment. One such formulation is <i>Vaalai Rasa Mezhugu</i>, it is widely used to treat various cancers including testicular cancer. But scientific proof of the therapeutic efficacy of <i>Vaalai Rasa Mezhugu</i> is not available. Hence current study was carried out to evaluate the anti-cancer property of <i>Vaalai Rasa Mezhugu</i> using TM3 cell lines, by estimating its antiproliferative activity through MTT assay and Apoptosis by annexin V flow cytometry. The findings revealed a dose- dependent cytotoxic effect (LC<sub>50</sub> value-4.2163µg/ml), significant late apoptotic effect (52.90%). These findings reveal the utility of <i>Vaalai Rasa Mezhugu</i> in testicular cancer. Future clinical study will be conducted to evaluate safety and efficacy of <i>Vaalai Rasa Mezhugu</i> in human subjects which will in turn highlight its role as a novel anti-cancer drug from Traditional medicine.
Show more [+] Less [-]Bibliographic information
This bibliographic record has been provided by Visagaa Publishing House
